increasing glp 1 Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP-1 Receptor Agonist Market Growth
Description
Kahles F, Liberman A, Halim C, et al
The fact that it is now achievable with a weekly injection represents one of the most significant advances in metabolic medicine in decades
and the regulatory picture is actively shifting with the 503B comment period closing June 29
A Tier 4 medication is not "worse" than Tier 1
Variants in GLP1R, GIPR, FTO, and MC4R may correlate with differential response patterns
Besides, akin to GLP1, GIP demonstrates a glucosedependent effect on insulin secretion [127], implying that GIP could function in the antihyperglycemic effect of DPP4i
